A beautiful autumn for Covid-19 test makers
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Exact chases its dream with $1.7bn Thrive deal
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Lilly swerves the worst case for its Covid-19 antibody
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
Roche and Lilly most vested in research
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
A listless quarter for Medtronic
Medtronic has lined up a whole pipeline of new devices – and it will need them.
